FACSymphony S6 Cell Sorter for Improving Basic, Clinical, and Translational Cancer Research Capabilities
FACSymphony S6 Cell Sorter for Improving Basic, Clinical, and Translational Cancer Research Capabilities
批准号:
10427630
负责人:
Robert A.J. Signer
金额:
$59.98万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-01 至 2024-07-31
关键词:
13 year oldAgeAnimal ExperimentsBiomedical ResearchCaliforniaCancer CenterCell Culture TechniquesCell SeparationCellsChargeClinicalColorCommunitiesContract ServicesCore FacilityEnsureFlow CytometryFlow Cytometry Shared ResourceFundingHourHumanImpairmentLasersLeadershipMissionModernizationNCI Center for Cancer ResearchPopulationResearchResearch PersonnelSafetySamplingSideSorting - Cell MovementSpeedTechnologyTrainingTraining and EducationUniversitiesVisionanticancer researchbasecost efficientfaculty researchimprovedinstrumentinstrumentationmeetingsprogramstranslational cancer research
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
The Flow Cytometry Shared Resource (FCSR) is a comprehensive core facility that has been an integral
component of the Moores Cancer Center (MCC) at the University of California, San Diego (UCSD) since 1990.
It serves all MCC research programs and the La Jolla biomedical research community at large with ready access
to high-speed flow cytometry-based analysis and cell sorting of dissociated cell populations from clinical
samples, animal experiments, and cell culture studies. The FCSR has been a highly utilized and essential core
facility critical to diverse research programs in the MCC. Between 2013-2018, the FCSR served 59 MCC
investigators and was utilized for nearly 4000 hours by MCC investigators. However, recent advances in FACS
technology have rendered current sorters in the FCSR mostly obsolete and incapable of meeting state-of-the-
art research needs, which threatens to limit critical advances in cancer research. The two cell sorters located in
the FCSR, a BD FACSAria I and FACSAria II, are over 15 and 13 years old, respectively. BD no longer supports
service contracts for the FACSAria I, and as a consequence, the instrument has been rendered mostly
inoperative. While the FACSAria II is still somewhat operational, its age and configuration (4 laser, 13 color, 4-
way sorting) are insufficient to meet current research needs. In addition, the FACSAria II is not housed within a
biosafety cabinet, which limits its use for sorting certain biohazardous samples, including some human clinical
samples. With these shortcomings recognized by senior MCC leadership, a comprehensive plan to revitalize the
FCSR was developed. Towards that end, they have appointed Dr. Signer as the new co-Director of the FCSR in
charge of new instrumentation. Funds are requested to acquire the BD FACSymphony S6 high parameter cell
sorter, a bench-top high speed cell sorter equipped with five lasers (355, 405, 488, 561, and 637 nm) capable of
analyzing up to 23 different colors plus forward and side scatter. The FACSymphony will be contained within a
Baker Class II Type A2 biosafety cabinet to meet safety and regulatory requirements for sorting clinical samples.
This instrument represents a crucial early step in advancing the MCC senior leaders’ vision to modernize the
MCC FCSR. The BD FACSymphony S6 cell sorter when combined with the expertise, leadership, and training
plans of Dr. Signer and staff will ensure that researchers at UCSD and within the surrounding scientific
community once again have access 24 hours a day, 7 days a week, 365 days a year to the cell sorting technology
they need to carry out high-impact cancer research. Without this instrument, the FCSR will continue to have
severely limited instrumentation, and MCC faculty research will be impaired. Acquisition of the BD
FACSymphony S6 cell sorter will enable the FCSR to continue its central mission to provide state-of-the-art
instrumentation, expert support, education, and training for MCC investigators and the La Jolla biomedical
research community in a highly effective, reliable and cost-efficient manner.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ex vivo hematopoietic stem cell growth mediated by the heat shock response
-
批准号:10116376
-
项目类别:
-
资助金额:$51.11万
-
财政年份:2020
-
负责人:Robert A.J. Signer
-
依托单位:
Ex vivo hematopoietic stem cell growth mediated by the heat shock response
-
批准号:10544515
-
项目类别:
-
资助金额:$51.19万
-
财政年份:2020
-
负责人:Robert A.J. Signer
-
依托单位:
Ex vivo hematopoietic stem cell growth mediated by the heat shock response
-
批准号:10319623
-
项目类别:
-
资助金额:$51.19万
-
财政年份:2020
-
负责人:Robert A.J. Signer
-
依托单位:
Protein Homeostasis in Hematopoietic Stem Cells
-
批准号:10407580
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2018
-
负责人:Robert A.J. Signer
-
依托单位:
Protein Homeostasis in Hematopoietic Stem Cells
-
批准号:10203945
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2018
-
负责人:Robert A.J. Signer
-
依托单位:
Protein homeostasis in hematopoietic stem cells
-
批准号:10660341
-
项目类别:
-
资助金额:$23.7万
-
财政年份:2018
-
负责人:Robert A.J. Signer
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: